FindTrial
Sign In

Evaluation the efficasy of Boswellia serrata on patients with mild to moderate Alzheimer disease

Evaluation the efficasy of Boswellia serrata on patients with mild to moderate Alzheimer disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015051822306N1
Enrollment
Unknown
Registered
2016-05-12
Start date
2015-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with mild to moderate Alzheimer. Alzheimer disease, unspecified

Interventions

Intervention 1: Control group:6 placebo capsules daily. Intervention 2: Intervention group:6 kondor capsules daily.
Treatment - Drugs
Control group:6 placebo capsules daily
Intervention group:6 kondor capsules daily

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: mild to moderate Alzheimer disease patients Exclusion criteria: parkinson; multiple sclorosis; heart failure stage C and D of AHA/ACC classification; ischemic heart disease; uncontrolled hypertension; schizophrenia; active peptic ulcer; uncontrolled diabetes and alcohol abuse.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Memory. Timepoint: at the first and every month up to 3 months. Method of measurement: CDR (clinical dementia rating).—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Asadi

Shiraz University of Medical Sciences

asadi_s@sums.ac.ir+98 71 3242 4128

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026